Oncology
Latest news
826 articles · 20 / page
Higher Osteoradionecrosis Risk After Proton Therapy than IMRT in Oropharyngeal Cancer — What Clinicians Should Know
In a large single‑institution cohort of oropharyngeal squamous cell carcinoma, proton therapy was associated with a higher 3‑year rate of osteoradionecrosis than IMRT (6.4% vs 2.7%), though severe ORN remained uncommon.
Hidden Burden: Nearly 1 in 10 Adolescents and Young Adults Develop Metastatic Recurrence — Survival Often Worse Than De Novo Metastasis
A California cohort study found a 5-year cumulative incidence of metastatic recurrence of 9.5% among adolescents and young adults (AYAs) initially diagnosed with nonmetastatic cancer; recurrence risk and post-recurrence survival varied mark
PLCOm2012 Risk-Based Selection Outperforms NELSON Criteria for Lung Cancer Detection in Germany: Findings from the HANSE Cohort
In HANSE, PLCOm2012 (6‑year risk ≥1.58%) selected more lung cancers and yielded a lower number needed to screen than NELSON criteria, supporting risk-model selection for CT screening programs, with caveats on generalisability and mortality
How Cancer Turns Nerves Against Immunity — and a New Strategy That Could Both Relieve Pain and Boost Immunotherapy
A Cell study shows head and neck cancers hijack a nerve→lymph node circuit (ATF4→SLIT2→sensory neurons→CGRP) to suppress immunity and cause pain — suggesting nerve-targeting drugs could both ease pain and improve immunotherapy.
Atorvastatin Preserves Aortic Elasticity During Anthracycline Chemotherapy: Secondary Analysis of STOP‑CA
In a secondary analysis of the randomized STOP‑CA trial, atorvastatin 40 mg daily attenuated anthracycline‑associated increases in aortic stiffness measured by CMR pulse wave velocity, suggesting vascular protection and a potential strategy
International Reference Values for Total Pancreatectomy Show Higher Perioperative Risk Than Pancreatoduodenectomy — Practical Benchmarks for Quality Control
This multicenter study defines international perioperative reference values for total pancreatectomy (TP). Even low‑risk TP carries higher morbidity and mortality than pancreatoduodenectomy; outcomes worsen with vascular resection or conver
Thyroid Cancer in Adolescents and Young Adults Is Surging Worldwide — But Deaths Aren’t: Strong Evidence of Overdiagnosis from a 185‑Country Analysis
A 185-country study shows large, sustained increases in thyroid cancer incidence among adolescents and young adults (15–39 years) since the 2000s while mortality remains low and stable — a pattern most consistent with widespread overdiagnos
High, Persistent Breast Cancer Mortality in Sub‑Saharan Africa: 7‑Year ABC‑DO Cohort Reveals Major Survival Gaps and Actionable Targets
A 7‑year follow-up of 2,153 women in the ABC‑DO cohort shows poor breast cancer survival in much of sub‑Saharan Africa, with 5‑year crude survival 40% and marked between-country and racial disparities; reaching WHO stage downstaging targets
Severe Late Radiation Toxicities in Head and Neck Cancer: Common, Preventable, and Linked to Worse Survival
A large single-center cohort (n=7,622) shows 12.6% of head and neck cancer patients develop severe (≥RTOG grade 3) radiation-related late toxicities; modifiable factors and specialized multidisciplinary late-effects care may reduce risk and
Nationwide China Study Reveals Age-Specific Burden and Survival Gaps in Acute Leukaemia: Good Outcomes for Children and APL; Poor Prognosis in Older Adults
A large linkage of Chinese national registries (628.4 million population) estimates 43,275 acute leukaemia cases in 2019, describes age-specific incidence peaks in early childhood and older age, reports major survival gains for children and
Neoadjuvant Chidamide plus Anthracycline–Taxane Chemotherapy Yields a 35% RCB 0–I Rate in HR+/HER2– Breast Cancer: Early Phase 2 Results from MUKDEN 05
In a multicentre phase 2 single-arm trial, oral chidamide added to standard epirubicin–cyclophosphamide followed by docetaxel produced an RCB 0–I rate of 35.2% in stage II–III HR+/HER2– breast cancer, with high rates of grade 3–4 neutropeni
Most Adolescents and Young Adults with Solid Tumours Reach Near-Normal 5-Year Survival Within Four Years — Implications for ‘Right to be Forgotten’ Policies
Population-based Dutch data show that AYA survivors of most solid malignancies achieve five-year conditional relative survival >95% by four years post-diagnosis, supporting reconsideration of blanket 10‑year disclosure periods in Right to B
Oral KRAS G12D inhibitor GFH375 produces ORR 40.7% and DCR 96.7% in previously treated KRAS G12D pancreatic ductal adenocarcinoma: Key readouts from ESMO 2025
A global phase I/II study of oral GFH375 in previously treated KRAS G12D mutant PDAC showed a 40.7% ORR, 96.7% DCR, median PFS 5.52 months, and manageable toxicity, supporting ongoing phase III evaluation.
Prediabetes Pathways: Age-Driven Trajectories to Type 2 Diabetes, Cancer, and Death in 328,000 Adults — What Clinicians Need to Know
A 20-year multistate analysis of 328,049 adults with prediabetes in England shows age strongly shapes progression to type 2 diabetes, cancer, and death, with younger patients likely to remain in prediabetes—highlighting windows for tailored
Preoperative PAXG Improves Event‑Free Survival over mFOLFIRINOX in Resectable and Borderline Resectable Pancreatic Cancer: First Randomisation Results from PACT‑21 CASSANDRA
In the multicentre phase 3 PACT‑21 CASSANDRA trial, preoperative PAXG significantly prolonged event‑free survival versus mFOLFIRINOX in resectable and borderline resectable pancreatic ductal adenocarcinoma, with comparable high‑grade toxici
One in Three Head and Neck Cancer Survivors Still Have Supportive Care Needs at Five Years — Fear of Recurrence and Pain Drive Long-Term Demand
Longitudinal data from 403 head and neck cancer survivors show that while information and health-system needs decline between years 2 and 5, one-third report at least one moderate-to-high unmet supportive care need at year 5—notably fatigue
Half of Long‑Term Head and Neck Cancer Survivors Report Unmet Supportive Care Needs — A Multinational Cohort Highlights Clinical and System Drivers
A multinational cross‑sectional study of 1,097 head and neck cancer survivors >5 years after diagnosis found that ~50% report moderate‑to‑high unmet supportive care needs, driven by HNC‑specific, psychological and physical/daily living conc
Dutch Nationwide Registry Shows Large Health-System Burden and Early Progression Risk in Advanced Cutaneous Squamous Cell Carcinoma
The Dutch Keratinocyte Cancer Collaborative (DKCC) provides the first nationwide longitudinal real-world dataset of advanced cutaneous squamous cell carcinoma (CSCC), estimating that 8% of CSCC are locally advanced and demonstrating short m
Zanidatamab Shows Durable Activity and Pain Benefit in HER2‑Positive Metastatic Biliary Tract Cancer: Final HERIZON‑BTC‑01 Results
Final HERIZON‑BTC‑01 data show zanidatamab induces durable responses and a median overall survival of 15.5 months in previously treated HER2‑overexpressing metastatic biliary tract cancer, with greatest benefit in IHC 3+ tumors and manageab
Balancing Benefit and Harm: How Long Should Androgen Deprivation Therapy Be Given With Radiotherapy for Localized Prostate Cancer?
An individual-patient data meta-analysis of 10,266 men shows nonlinear oncologic benefit from longer ADT with radiotherapy (diminishing beyond 9–12 months) but increasing other-cause mortality with long-term ADT; optimal duration should be
Browse by specialty
Open language-specific specialty feeds and department pages.